Management of Prolonged QTc Interval Due to Escitalopram Overdose

Initial Management

The American College of Cardiology recommends discontinuing escitalopram immediately as it is the offending agent causing QT prolongation, and implementing continuous cardiac monitoring until drug levels have decreased and QT prolongation resolves 1, 2
The American Heart Association suggests obtaining baseline ECG and monitoring QTc interval regularly (at least every 8-12 hours, more frequently if QTc continues to prolong) 2
Correction of electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, is essential in the management of escitalopram overdose 1, 3, 4

The American College of Cardiology recommends continuing ECG monitoring for at least 48 hours after ingestion, as QTc normalization may take more than 2 days, and monitoring until QTc returns to normal range (<430 ms for males, <450 ms for females) 3, 4
Patients with QTc >500 ms or >60 ms increase from baseline are at highest risk for torsades de pointes, according to the American College of Cardiology 3, 4

The American College of Cardiology suggests administering IV magnesium (2g) as the initial drug of choice for treating or preventing torsades de pointes, regardless of serum magnesium level 4

The American College of Cardiology recommends administering 2g of IV magnesium as first-line treatment for torsades de pointes, and considering non-synchronized defibrillation if hemodynamically unstable 4
For bradycardia-induced torsades, the American College of Cardiology suggests overdrive pacing with short-term pacing rates of 90-110 bpm, or IV isoproterenol titrated to heart rates >90 bpm if temporary pacing is not immediately available 4

The European Society of Cardiology advises avoiding administering other QT-prolonging medications during the treatment period 4, 5
Lorazepam can be safely used for sedation in these patients as it does not prolong the QT interval, according to the American College of Cardiology 6

The American College of Cardiology identifies higher risk of complications with QTc >500 ms, increase in QTc >60 ms from baseline, presence of other QT-prolonging medications, electrolyte abnormalities, female gender, and bradycardia or heart block 1, 2, 3, 4, 5